ライフサイエンスコーパス: FcepsilonRII

1 its two Fc receptors, FcepsilonRI and CD23 (FcepsilonRII).

2 through two receptors, FcepsilonRI and CD23 (FcepsilonRII).

3 me 19p13 adjacent to the C-type lectin CD23 (FcepsilonRII).

4 s that they are important sources of soluble FcepsilonRII.

5 ified that IgE immune complex stimulation of FcepsilonRII activated intracellular tyrosine phosphoryl

6 increasingly recognized, the consequences of FcepsilonRII activation are not completely understood.

7 In humans, the FcepsilonRII B isoform on epidermal Langerhans cells is

8 FcepsilonRII-bearing monocytes and B cells expressed hig

9 inity immunoglobulin E (IgE) receptor, CD23 (FcepsilonRII), binds both IgE and CD21 and, through thes

10 inding to the B cell receptor for IgE, CD23 (FcepsilonRII), but in contrast, binding of the anti-IgE

11 The low-affinity receptor for IgE, FcepsilonRII (CD 23), plays an important role in IgE-med

12 The low-affinity receptor for IgE, FcepsilonRII (CD23), contributes to allergic inflammatio

13 The low affinity IgE receptor, FcepsilonRII (CD23), is both a positive and negative reg

14 gE Abs, and agonist Abs against FcepsilonRI, FcepsilonRII/CD23 and galectin-3.

15 s interaction with its low-affinity receptor FcepsilonRII/CD23, affecting serum clearance and antigen

16 nd CD8(+) T cells; CD20(+) B cells; CD23(+) (FcepsilonRII) cells; IL-4; IL-5; eosinophils, and vascul

17 Conversely, in vivo CD23 (FcepsilonRII) expression on eosinophils was decreased in

18 also known as the low affinity IgE receptor (FcepsilonRII), has been hypothesized to have a role in I

19 ng mAb to the low affinity receptor for IgE, FcepsilonRII (i.e., CD23) or by depleting the sensitizin

20 FcepsilonRII is a multifunctional low-affinity IgER that

21 In this study, we show that CD23 (FcepsilonRII) is constitutively expressed in established

22 FcepsilonRIIa, which is the major FcepsilonRII isoform in mice, was found to be constituti

23 thway in allergic responses and suggest that FcepsilonRII may play a role in regulating allergic reac

24 FcepsilonRII-mediated allergen-IgE complex uptake by B c

25 Although discrepancies in FcepsilonRII-mediated functions are being increasingly r

26 and DPG-POL-Phl p to elicit FcepsilonRI- and FcepsilonRII-mediated IgE responses was measured by baso

27 Importantly, FcepsilonRII-mediated signaling by allergen-IgE immune c

28 Together, our results demonstrate that FcepsilonRII mediates cell type-dependent function in al

29 Finally, the up-regulated mRNA expression of FcepsilonRII observed following exposure of TSM to atopi

30 n this study, we evaluated the expression of FcepsilonRII on human blood cells and found that it was

31 nd basophils and low-affinity IgE receptors (FcepsilonRII) on B cells.

32 lonRI on mast cells and basophils, and CD23 (FcepsilonRII) on B cells.

33 Furthermore, FcepsilonRII predominantly bound allergen-IgE complexes

34 the autologous expression and activation of FcepsilonRII receptors in the airway smooth muscle itsel

35 tes and B cells expressed high levels of the FcepsilonRII sheddase a disintegrin and metalloproteinas

36 r of FcepsilonRII, was administered in vivo, FcepsilonRII-specific mRNA and protein was significantly

37 esults identify a novel allergen-IgE complex/FcepsilonRII/Syk/IFN-gamma pathway in allergic responses

38 T-cell responses in mice by targeting CD23 (FcepsilonRII), the low-affinity receptor for IgE on B ce

39 CD23/FcepsilonRII, the low-affinity receptor for IgE, is cons

40 De novo synthesis of FcepsilonRII was also induced in vitro by interleukin-4

41 of atopic dermatitis, we determined whether FcepsilonRII was also present on murine Langerhans cells

42 When interleukin-4, a known inducer of FcepsilonRII, was administered in vivo, FcepsilonRII-spe

43 induced mRNA and cell surface expression of FcepsilonRII, whereas constitutive expression of the IgG